Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of fenfluramine for rare seizure disorders including Dravet syndrome and Lennox-Gastaut syndrome
NL-OMON60158Phase 3Completed
- Sponsor
- Zogenix, Inc.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fenfluramine in Dravet syndrome, Lennox-Gastaut syndrome (LGS) and epileptic encephalopathy, sponsored by Zogenix, Inc. Primary endpoints: Adverse events, Laboratory safety and 8 more. Started Sep 2020; status: completed.
02
Drugs
fenfluramine
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)epileptic encephalopathy
Beyond the preview
Go deeper on NL-OMON60158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60158.